tiprankstipranks
Advertisement
Advertisement
Remepy Advances Hybridopa Toward Phase III With New Mechanistic Data in Parkinson’s Disease
PremiumPrivate CompaniesRemepy Advances Hybridopa Toward Phase III With New Mechanistic Data in Parkinson’s Disease
1M ago
Remepy Showcases Hybrid Drug Concept at Tech Tour Growth Health Event
Premium
Private Companies
Remepy Showcases Hybrid Drug Concept at Tech Tour Growth Health Event
1M ago
Remepy Advances Hybridopa Toward Phase 3 as TGCT App Gains Clinical Spotlight
Premium
Private Companies
Remepy Advances Hybridopa Toward Phase 3 as TGCT App Gains Clinical Spotlight
2M ago
Remepy Showcases TGCT & Me Patient Support App at Major Oncology Conference
PremiumPrivate CompaniesRemepy Showcases TGCT & Me Patient Support App at Major Oncology Conference
2M ago
Remepy’s TGCT & Me App Highlighted at Major Oncology Conference
Premium
Private Companies
Remepy’s TGCT & Me App Highlighted at Major Oncology Conference
2M ago
Remepy – Weekly Recap
Premium
Private Companies
Remepy – Weekly Recap
2M ago
Remepy Highlights Positive Phase IIa Results for Hybridopa in Parkinson’s Disease
PremiumPrivate CompaniesRemepy Highlights Positive Phase IIa Results for Hybridopa in Parkinson’s Disease
3M ago
Remepy Advances Hybrid Parkinson’s Therapy as Phase IIa Trial Hits Key Milestones
Premium
Private Companies
Remepy Advances Hybrid Parkinson’s Therapy as Phase IIa Trial Hits Key Milestones
3M ago
Remepy Targets 2026 Phase 3 Trial for Parkinson’s Candidate Hybridopa
Premium
Private Companies
Remepy Targets 2026 Phase 3 Trial for Parkinson’s Candidate Hybridopa
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100